JP2013544254A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013544254A5 JP2013544254A5 JP2013539982A JP2013539982A JP2013544254A5 JP 2013544254 A5 JP2013544254 A5 JP 2013544254A5 JP 2013539982 A JP2013539982 A JP 2013539982A JP 2013539982 A JP2013539982 A JP 2013539982A JP 2013544254 A5 JP2013544254 A5 JP 2013544254A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- receptor antagonist
- chemotherapeutic agent
- prolactin receptor
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/948,329 US8648046B2 (en) | 2009-02-26 | 2010-11-17 | Compositions and methods for visualizing and eliminating cancer stem cells |
| US12/948,329 | 2010-11-17 | ||
| PCT/US2011/061040 WO2012068282A1 (en) | 2010-11-17 | 2011-11-16 | Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015227552A Division JP2016029110A (ja) | 2010-11-17 | 2015-11-20 | 卵巣がんを治療するためのプロラクチン受容体拮抗薬および化学療法剤の使用 |
| JP2018008262A Division JP2018062527A (ja) | 2010-11-17 | 2018-01-22 | 卵巣がんを治療するためのプロラクチン受容体拮抗薬および化学療法剤の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013544254A JP2013544254A (ja) | 2013-12-12 |
| JP2013544254A5 true JP2013544254A5 (https=) | 2014-12-18 |
| JP6306886B2 JP6306886B2 (ja) | 2018-04-04 |
Family
ID=45349276
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013539982A Expired - Fee Related JP6306886B2 (ja) | 2010-11-17 | 2011-11-16 | 卵巣がんを治療するためのプロラクチン受容体拮抗薬および化学療法剤の使用 |
| JP2015227552A Pending JP2016029110A (ja) | 2010-11-17 | 2015-11-20 | 卵巣がんを治療するためのプロラクチン受容体拮抗薬および化学療法剤の使用 |
| JP2018008262A Withdrawn JP2018062527A (ja) | 2010-11-17 | 2018-01-22 | 卵巣がんを治療するためのプロラクチン受容体拮抗薬および化学療法剤の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015227552A Pending JP2016029110A (ja) | 2010-11-17 | 2015-11-20 | 卵巣がんを治療するためのプロラクチン受容体拮抗薬および化学療法剤の使用 |
| JP2018008262A Withdrawn JP2018062527A (ja) | 2010-11-17 | 2018-01-22 | 卵巣がんを治療するためのプロラクチン受容体拮抗薬および化学療法剤の使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8648046B2 (https=) |
| EP (1) | EP2640412B1 (https=) |
| JP (3) | JP6306886B2 (https=) |
| KR (1) | KR20140009196A (https=) |
| CN (2) | CN103298481A (https=) |
| AU (1) | AU2011328935B2 (https=) |
| CA (1) | CA2817846A1 (https=) |
| IL (1) | IL226271A (https=) |
| WO (1) | WO2012068282A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013167750A2 (en) * | 2012-05-11 | 2013-11-14 | Prorec Bio Ab | Method for diagnosis and treatment of prolactin associated disorders |
| CN105102480B (zh) | 2012-12-24 | 2019-04-16 | 艾伯维公司 | 催乳素受体结合蛋白及其用途 |
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| EP3707166A4 (en) * | 2017-11-06 | 2021-11-24 | Daniel J. Monticello | CHEMICAL ANTIGENIC RECEPTOR SYSTEMS WITH NEGATIVE DOMINANT LIGAND |
| WO2019169330A1 (en) * | 2018-03-02 | 2019-09-06 | Oncolix, Inc. | Method for treating cancers expressing prolactin receptor |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| CN113956356B (zh) * | 2021-10-27 | 2023-05-02 | 福州迈新生物技术开发有限公司 | 抗prl蛋白单克隆抗体、细胞系及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1055932A (en) | 1975-10-22 | 1979-06-05 | Hematech Inc. | Blood substitute based on hemoglobin |
| DE2616086C2 (de) | 1976-04-13 | 1986-04-03 | Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg | Substanz zur Verwendung in einem kolloidalen Blutvolumenersatzmittel aus Hydroxyethylstärke und Hämoglobin |
| EP1079851B1 (en) * | 1998-05-12 | 2007-07-04 | Greenville Hospital System | Use of anti-prolactin agents to treat cancer |
| EP2180054A1 (en) * | 1999-12-24 | 2010-04-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| EP1282642B1 (en) * | 2000-05-09 | 2006-09-06 | Greenville Hospital System | Therapeutic pore-forming peptides |
| US7001888B2 (en) * | 2002-03-29 | 2006-02-21 | Threshold Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
| BR0314106A (pt) | 2002-09-11 | 2005-07-19 | Fresenius Kabi De Gmbh | Polipeptìdeos hasilados, especialmente eritropoietina hasilada |
| NZ541122A (en) * | 2002-12-26 | 2008-09-26 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| US8754031B2 (en) * | 2004-03-08 | 2014-06-17 | Oncolix, Inc. | Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway |
| US20050238628A1 (en) * | 2004-04-08 | 2005-10-27 | Blau Carl A | Methods for treating cancer |
| US7422899B2 (en) * | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
| CN100479863C (zh) * | 2006-09-06 | 2009-04-22 | 中国医学科学院北京协和医院 | Cofilin 1与癌症的紫杉烷类化疗药物耐药性的相关性 |
| EP2094291A1 (en) * | 2006-12-21 | 2009-09-02 | Novo Nordisk A/S | Dimeric prolactin receptor ligands |
| WO2009089537A2 (en) * | 2008-01-11 | 2009-07-16 | Northwestern University | Anti-cancer compounds |
| US8754035B2 (en) * | 2009-02-26 | 2014-06-17 | Oncolix, Inc. | Compositions and methods for visualizing and eliminating cancer stem cells |
-
2010
- 2010-11-17 US US12/948,329 patent/US8648046B2/en not_active Expired - Fee Related
-
2011
- 2011-11-16 CA CA2817846A patent/CA2817846A1/en not_active Abandoned
- 2011-11-16 US US13/988,014 patent/US20130231286A1/en not_active Abandoned
- 2011-11-16 WO PCT/US2011/061040 patent/WO2012068282A1/en not_active Ceased
- 2011-11-16 CN CN2011800552054A patent/CN103298481A/zh active Pending
- 2011-11-16 AU AU2011328935A patent/AU2011328935B2/en not_active Ceased
- 2011-11-16 KR KR1020137013005A patent/KR20140009196A/ko not_active Ceased
- 2011-11-16 EP EP11796851.1A patent/EP2640412B1/en not_active Not-in-force
- 2011-11-16 JP JP2013539982A patent/JP6306886B2/ja not_active Expired - Fee Related
- 2011-11-16 CN CN201610675696.7A patent/CN106177915A/zh active Pending
-
2013
- 2013-05-09 IL IL226271A patent/IL226271A/en active IP Right Grant
-
2015
- 2015-11-20 JP JP2015227552A patent/JP2016029110A/ja active Pending
-
2018
- 2018-01-22 JP JP2018008262A patent/JP2018062527A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013544254A5 (https=) | ||
| Song et al. | Advances in aptamer-based nuclear imaging | |
| EP2764406B1 (en) | Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties | |
| JP2018058847A5 (https=) | ||
| EP3679128A1 (en) | Method of targeting exosomes | |
| ME02806B (me) | Protutijela protiv csf-1r | |
| WO2007117467B1 (en) | Use of tm-601 for the diagnosis and treatment of tumors | |
| WO2014059199A1 (en) | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence | |
| TW201247710A (en) | Tumor-targeting peptides and their uses in detecting and treating cancers | |
| Aranda-Lara et al. | Synthesis and evaluation of Lys1 (α, γ-Folate) Lys3 (177Lu-DOTA)-Bombesin (1-14) as a potential theranostic radiopharmaceutical for breast cancer | |
| MX2013010012A (es) | Analogos de octreotato radiomarcado como trazadores de tomografia por emision de positrones. | |
| PH12013500270A1 (en) | Peptide radiotracer compositions | |
| HRP20210922T1 (hr) | Konjugati protutijela protiv met s lijekom | |
| JP2021510701A (ja) | 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤 | |
| EP3166967B1 (en) | Synthetic somatostatin receptor ligands | |
| KR102033920B1 (ko) | 급성 골수성 백혈병을 치료하는 방법 | |
| TWI605815B (zh) | 用於製備包含阿米福丁與胺基酸之腎保護劑的組成物及方法 | |
| JP2012519168A5 (https=) | ||
| WO2020031136A1 (en) | Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer | |
| Zhong et al. | Recent progress in peptide-based fluorescent probes biomedical applications: A review | |
| CN103800923B (zh) | 一种肿瘤双靶点放射性分子探针及其制备方法 | |
| Xiao et al. | Trojan-like peptide drug conjugate design and construction for application in treatment of triple-negative breast cancer | |
| Naqvi et al. | Novel indium-111 labeled gastrin peptide analogues (MG-CL1-4): synthesis and quality control | |
| R. Sivashankari et al. | Peptides to target tumor vasculature and lymphatics for improved anti-angiogenesis therapy | |
| Hlongwa et al. | The advent of Astatine-211 in targeted radionuclide therapy in prostate cancer: will it come to true fruition? |